Generate Biomedicines partners with Zealand Pharma on AI-designed metabolic disease therapies
ZEAL•Generate Biomedicines and Zealand Pharma will develop AI-engineered protein therapeutics for obesity and other metabolic diseases. The deal includes $30 million upfront, up to $35 million in early preclinical milestones and nearly $1.2 billion in total milestones, plus tiered royalties on two initial programs.
1. Deal terms
The multi-target collaboration will combine Zealand Pharma’s metabolic expertise with Generate Biomedicines’ generative AI and experimental validation platform to develop multispecific protein therapeutics. Generate will receive $30 million upfront, up to $35 million in early preclinical milestones and up to nearly $1.2 billion in total milestones, as well as tiered royalties on two initial programs. It also has an option to add a third program.
